# Kamlanoflast In Amyotrophic Lateral Sclerosis

> **NCT07396818** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Inflammasome Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- ALS (Amyotrophic Lateral Sclerosis)
- ALS
- Neuro-Degenerative Disease
- Neuro-Degenerative Diseases
- Motor Neuron Disease (MND)

## Interventions

- **DRUG:** Kamlanoflast
- **DRUG:** Kamlanoflast

## Key facts

- **NCT ID:** NCT07396818
- **Lead sponsor:** Inflammasome Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07396818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07396818, "Kamlanoflast In Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07396818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*